Biogen Reports Phase 2 Results for Felzartamab in IgA Nephropathy

Biogen today announced results from the Phase 2 IGNAZ trial evaluating felzartamab in patients with IgA nephropathy (IgAN). The trial demonstrated significant reductions in proteinuria, as measured by urine protein-to-creatinine ratio, compared to placebo at week 36.